Zobrazeno 1 - 10
of 2 336
pro vyhledávání: '"M. Kas"'
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-14 (2023)
Abstract Congenital disorders of glycosylation (CDG) are rare genetic disorders with a spectrum of clinical manifestations caused by abnormal N-glycosylation of secreted and cell surface proteins. Over 130 genes are implicated and next generation seq
Externí odkaz:
https://doaj.org/article/4e4c9c0d95cd406caa41b947b1337197
Publikováno v:
Knowledge and Information Systems. 65:435-462
Autor:
Sjoerd Klarenbeek, Chris W. Doornebal, Sjors M. Kas, Nicola Bonzanni, Jinhyuk Bhin, Tanya M. Braumuller, Ingrid van der Heijden, Mark Opdam, Philip C. Schouten, Kelly Kersten, Roebi de Bruijn, Daniel Zingg, Julia Yemelyanenko, Lodewyk F.A. Wessels, Karin E. de Visser, Jos Jonkers
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Effective treatment of invasive lobular carcinoma (ILC) of the breast is hampered by late detection, invasive growth, distant metastasis, and poor response to chemotherapy. Phosphoinositide 3-kinase (PI3K) signaling, one of the major druggable oncoge
Externí odkaz:
https://doaj.org/article/54b9a172c50d4990871cfc2608c09c9c
Publikováno v:
International Journal of Multimedia Information Retrieval. 11:639-651
Publikováno v:
IEEE Transactions on Intelligent Transportation Systems. 23:5360-5373
The ability to sense and understanding the driving environment is a key technology for ADAS and autonomous driving. Human drivers have to pay more visual attention to important or target elements and ignore unnecessary ones present in their field of
Autor:
Jos Jonkers, Lodewyk F.A. Wessels, Anton Berns, Koen van de Wetering, Sjoerd Klarenbeek, Paul D. Smith, Christopher Phillips, Sunny Mahakena, Renske de Korte-Grimmerink, Anne Paulien Drenth, Ellen Wientjens, Lorenzo Bombardelli, Eva Schut, Koen Schipper, Julian R. de Ruiter, Sjors M. Kas
Overview of the sequenced tumor samples, including sample IDs, treatment information and the type of transplanted material.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::063d7df9f07a1fa8d3aa0403c939654b
https://doi.org/10.1158/0008-5472.22419534.v1
https://doi.org/10.1158/0008-5472.22419534.v1
Autor:
Jos Jonkers, Lodewyk F.A. Wessels, Anton Berns, Koen van de Wetering, Sjoerd Klarenbeek, Paul D. Smith, Christopher Phillips, Sunny Mahakena, Renske de Korte-Grimmerink, Anne Paulien Drenth, Ellen Wientjens, Lorenzo Bombardelli, Eva Schut, Koen Schipper, Julian R. de Ruiter, Sjors M. Kas
This file describes Supplementary experimental details regarding the cell viability, clonogenic and competition assays, preparation of membrane vesicles and vesicular transport assays, immunohistochemistry, immunoblotting, RNA sequencing and analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d77b7b2b2de246dc1123abe29ebe0961
https://doi.org/10.1158/0008-5472.22419537.v1
https://doi.org/10.1158/0008-5472.22419537.v1
Autor:
Jos Jonkers, Lodewyk F.A. Wessels, Anton Berns, Koen van de Wetering, Sjoerd Klarenbeek, Paul D. Smith, Christopher Phillips, Sunny Mahakena, Renske de Korte-Grimmerink, Anne Paulien Drenth, Ellen Wientjens, Lorenzo Bombardelli, Eva Schut, Koen Schipper, Julian R. de Ruiter, Sjors M. Kas
Supplementary Figures S1-5 show additional information regarding the Fgfr2-Tbc1d1 fusion, the effect of AZD4547 on established WESB and WESB-Fgfr2 tumors and tumor-derived cells, the causes of death observed with the different AZD4547 treatment sched
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bae5c0fc93d8f79bf10c7614afc454ea
https://doi.org/10.1158/0008-5472.22419540.v1
https://doi.org/10.1158/0008-5472.22419540.v1
Autor:
Jos Jonkers, Lodewyk F.A. Wessels, Anton Berns, Koen van de Wetering, Sjoerd Klarenbeek, Paul D. Smith, Christopher Phillips, Sunny Mahakena, Renske de Korte-Grimmerink, Anne Paulien Drenth, Ellen Wientjens, Lorenzo Bombardelli, Eva Schut, Koen Schipper, Julian R. de Ruiter, Sjors M. Kas
In human cancers, FGFR signaling is frequently hyperactivated by deregulation of FGF ligands or by activating mutations in the FGFR receptors such as gene amplifications, point mutations, and gene fusions. As such, FGFR inhibitors are considered an a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09283a0aef426c5fd226ef4b115c3445
https://doi.org/10.1158/0008-5472.c.6510408.v1
https://doi.org/10.1158/0008-5472.c.6510408.v1
Autor:
Daniel Kaspar Zingg, Jinhyuk Bhin, Julia Yemelyanenko, Sjors M. Kas, Catrin Lutz, Chi-Chuan Lin, Sjoerd Klarenbeek, Jessica K. Lee, Ian M. Silverman, Stefano Annunziato, Marieke van de Ven, Siraj M. Ali, Timothy C. Burn, Shridar Ganesan, Lodewyk F. Wessels, Jos Jonkers
Publikováno v:
Cancer Research. 83:3488-3488
Human cancers frequently bear driver alterations in genes encoding receptor tyrosine kinases (RTKs), which has led to effective therapeutics targeting oncogenic signaling of RTK variants. Somatic hotspot mutations and structural amplifications and fu